In vitro activity of eravacycline against anaerobic bacteria isolated from clinically significant samples

IF 2.2 4区医学 Q3 INFECTIOUS DISEASES

Enfermedades infecciosas y microbiologia clinica Pub Date : 2026-04-01 Epub Date: 2026-02-05 DOI:10.1016/j.eimc.2026.503103

Fernando Cobo, Javier Rodríguez-Granger, Antonio Sampedro-Martínez, Juan Antonio Reguera-Márquez, José María Navarro-Marí

{"title":"In vitro activity of eravacycline against anaerobic bacteria isolated from clinically significant samples","authors":"Fernando Cobo, Javier Rodríguez-Granger, Antonio Sampedro-Martínez, Juan Antonio Reguera-Márquez, José María Navarro-Marí","doi":"10.1016/j.eimc.2026.503103","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><div>The objective of this study was to evaluate the <em>in vitro</em> activity of eravacycline against 173 anaerobic isolates and compare it with the activity of other antimicrobials used against infections caused by anaerobic microorganisms.</div></div><div><h3>Methods</h3><div>Minimal inhibitory concentrations (MICs) for eravacycline, delafloxacin, piperacillin–tazobactam, meropenem, clindamycin, metronidazole and amoxicillin–clavulanic acid were determined against 173 anaerobic bacterial isolates obtained from several types of human clinical specimens.</div></div><div><h3>Results</h3><div>MICs were lower for eravacycline than for all other antibiotics tested with the exception of delafloxacin against <em>Bacteroides</em>, <em>Prevotella</em>, Gram-positive anerobic cocci (GPACs) and <em>Clostridium</em> and piperacillin–tazobactam against <em>Clostridium</em>. Two (2.8%) isolates of <em>Bacteroides</em> spp. showed a MIC≥4μg/mL, along with two (22%) isolates of <em>Phocaeicola</em> spp. and two (11%) of GPACs.</div></div><div><h3>Conclusions</h3><div>With some exceptions, the present results show lower MICs for eravacycline in comparison to the other antibiotics used against anaerobes.</div></div>","PeriodicalId":11608,"journal":{"name":"Enfermedades infecciosas y microbiologia clinica","volume":"44 4","pages":"Article 503103"},"PeriodicalIF":2.2000,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Enfermedades infecciosas y microbiologia clinica","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0213005X26000121","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/2/5 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction

The objective of this study was to evaluate the in vitro activity of eravacycline against 173 anaerobic isolates and compare it with the activity of other antimicrobials used against infections caused by anaerobic microorganisms.

Methods

Minimal inhibitory concentrations (MICs) for eravacycline, delafloxacin, piperacillin–tazobactam, meropenem, clindamycin, metronidazole and amoxicillin–clavulanic acid were determined against 173 anaerobic bacterial isolates obtained from several types of human clinical specimens.

Results

MICs were lower for eravacycline than for all other antibiotics tested with the exception of delafloxacin against Bacteroides, Prevotella, Gram-positive anerobic cocci (GPACs) and Clostridium and piperacillin–tazobactam against Clostridium. Two (2.8%) isolates of Bacteroides spp. showed a MIC ≥ 4 μg/mL, along with two (22%) isolates of Phocaeicola spp. and two (11%) of GPACs.

Conclusions

With some exceptions, the present results show lower MICs for eravacycline in comparison to the other antibiotics used against anaerobes.

查看原文本刊更多论文

依瓦环素体外抗厌氧菌活性的研究

本研究的目的是评价依瓦环素对173株厌氧分离菌的体外活性，并将其与其他抗生素对厌氧微生物感染的活性进行比较。方法测定从不同类型人体临床标本中分离的173株厌氧菌对依瓦环素、德拉沙星、哌拉西林-他唑巴坦、美罗培南、克林霉素、甲硝唑和阿莫西林-克拉维酸的最低抑菌浓度（mic）。结果除德拉沙星对拟杆菌、普雷沃氏菌、革兰氏阳性厌氧菌（GPACs）和梭状芽孢杆菌和哌拉西林-他唑巴坦对梭状芽孢杆菌的抑制作用外，依瓦环素的mic值低于其他所有抗生素。2株（2.8%）Bacteroides spp. MIC≥4 μg/mL， 2株（22%）Phocaeicola spp.和2株（11%）GPACs。结论：除一些例外情况外，目前的结果显示，与其他用于治疗厌氧菌的抗生素相比，依拉瓦环素的mic较低。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Enfermedades infecciosas y microbiologia clinica 医学-传染病学

CiteScore

2.10

自引率

8.00%

发文量

194

审稿时长

29 days

期刊介绍： Hoy está universalmente reconocida la renovada y creciente importancia de la patología infecciosa: aparición de nuevos agentes patógenos, de cepas resistentes, de procesos con expresión clínica hasta ahora desconocida, de cuadros de una gran complejidad. Paralelamente, la Microbiología y la Infectología Clínicas han experimentado un gran desarrollo como respuesta al reto planteado por la actual patología infecciosa. Enfermedades Infecciosas y Microbiología Clínica es la Publicación Oficial de la Sociedad Española SEIMC. Cumple con la garantía científica de esta Sociedad, la doble función de difundir trabajos de investigación, tanto clínicos como microbiológicos, referidos a la patología infecciosa, y contribuye a la formación continuada de los interesados en aquella patología mediante artículos orientados a ese fin y elaborados por autores de la mayor calificación invitados por la revista.